XBRANE — Xbrane Biopharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK402.25m
- SEK363.27m
- SEK238.73m
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Interim Report | ARS | ARS | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 57.6 | 239 |
Cost of Revenue | |||||
Gross Profit | -18.3 | 0 | 0 | — | 35.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 187 | 217 | 181 | 224 | 561 |
Operating Profit | -187 | -217 | -181 | -166 | -322 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -188 | -218 | -183 | -169 | -322 |
Provision for Income Taxes | |||||
Net Income After Taxes | -188 | -218 | -183 | -169 | -322 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -188 | -226 | -188 | -173 | -388 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -188 | -226 | -188 | -173 | -388 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.85 | -1.37 | -0.88 | -0.747 | -1.27 |
Dividends per Share |